Takeshi Nakahara

Fukuoka, 8128582, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 225 publications

The Western Japan Atopic Dermatitis Registry (WJADR): A Multicenter Real-World Registry of Systemic Therapies for Atopic Dermatitis.

The Western Japan Atopic Dermatitis Registry (WJADR): A Multicenter Real-World Registry of Systemic Therapies for Atopic Dermatitis.

Journal: Journal of clinical medicine
Published: May 23, 2026

The Therapeutic Effect of Tapinarof on In Vitro Cutaneous Lupus-like Keratinocyte Model.

The Therapeutic Effect of Tapinarof on In Vitro Cutaneous Lupus-like Keratinocyte Model.

Journal: International journal of molecular sciences
Published: May 22, 2026

Prevalence, Severity, and Clinical Course of Atopic Dermatitis in Japan: A Web-Based Questionnaire Survey.

Prevalence, Severity, and Clinical Course of Atopic Dermatitis in Japan: A Web-Based Questionnaire Survey.

Journal: The Journal of dermatology
Published: April 26, 2026

Persistent Blood Dioxins and Sensory Impairment Assessed by Quantitative Sensory Testing in 115 Yusho Patients 57 Years After Exposure.

Persistent Blood Dioxins and Sensory Impairment Assessed by Quantitative Sensory Testing in 115 Yusho Patients 57 Years After Exposure.

Journal: The Journal of dermatology
Published: February 20, 2026

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor-Modulating Agent in the Treatment of Atopic Dermatitis.

Tapinarof as a Therapeutic Aryl Hydrocarbon Receptor-Modulating Agent in the Treatment of Atopic Dermatitis.

Journal: The Journal of dermatology
Published: February 20, 2026

Relationship between ovarian reserve and parental exposure in first-generation offspring of Yusho patients.

Relationship between ovarian reserve and parental exposure in first-generation offspring of Yusho patients.

Journal: Environment international
Published: December 17, 2025

Real-World, Single-Center Analysis of Cutaneous Adverse Events with Nemolizumab: Toward Safer and More Effective Use.

Real-World, Single-Center Analysis of Cutaneous Adverse Events with Nemolizumab: Toward Safer and More Effective Use.

Journal: Journal of clinical medicine
Published: November 17, 2025

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.

Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic Dermatitis.

Journal: Advances in therapy
Published: September 04, 2025

The Visualization of Nocturnal Scratching Behavior in Pediatric Atopic Dermatitis: Facilitating Shared Decision-Making and Assessing the Efficacy of Treatment.

The Visualization of Nocturnal Scratching Behavior in Pediatric Atopic Dermatitis: Facilitating Shared Decision-Making and Assessing the Efficacy of Treatment.

Journal: Cureus
Published: July 29, 2025

Habitual Scratching in Atopic Dermatitis and Its Association with Disease Severity: Findings from Japanese Health Insurance Claims and App-Based Data.

Habitual Scratching in Atopic Dermatitis and Its Association with Disease Severity: Findings from Japanese Health Insurance Claims and App-Based Data.

Journal: Dermatology and therapy
Published: July 21, 2025

Survey on the Actual Use of Topical Anti-Inflammatory Drugs Among Patients with Atopic Dermatitis.

Survey on the Actual Use of Topical Anti-Inflammatory Drugs Among Patients with Atopic Dermatitis.

Journal: Dermatology and therapy
Published: July 01, 2025

Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.

Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.

Journal: The Journal of dermatology
Published: June 20, 2025
Showing 1-12 of 225

Last Updated: 09/26/2026